The administration of EPO in cancer patients with anaemia revolutionised the treatment of this complication around 20 years ago with impressive results from a haematological perspective while simultaneously avoiding the adverse effects of blood transfusions in anaemic patients with cancer [138,139]. Here, EPO is linked to anemia.